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Abstract
Background: Biliary Atresia (BA) is rare and genetically complex, and the pathogenesis is elusive. The disease course is
variable and can represent heterogeneity, which hinders effective disease management. Deciphering the BA phenotypic
variance is a priority in clinics and can be achieved by the integrative analysis of genotype and phenotype. We aim to
explore the BA phenotypic features and to delineate the source of its variance.
Methods: The study is a cross-sectional observational study collating with case/control association analysis. One-hundred-
and-eighty-one type III non-syndromic BA patients and 431 controls were included for case–control association tests,
including 89 patients (47.19% males, born June 15th, 1981 to September 17th, 2007) have detailed clinical records with
follow-up of the disease course (median ~17.2 years). BA-association genes from the genome-wide gene-based
association test on common genetic variants (CV) and rare copy-number-variants (CNVs) from the genome-wide survey,
the later comprise only CNVs > 100 kb and found in the BA patients but not in the local population (N = 1,381) or the
database (N = 11,943). Hereby comorbidity is defined as a chronic disease that affects the BA patients but has no known
relationship with BA or with the BA treatment. We examined genotype-phenotype correlations of CNVs, connectivity of
these novel variants with BA-associated CVs, and their role in the BA candidate gene network.
Results: Of the 89 patients, 41.57% have comorbidities, including autoimmune-allergic disorders (22.47%). They carried 29
BA-private CNVs, including 3 CNVs underpinning the carriers’ immunity comorbidity and one JAG1 micro-deletion. The
BA-CNV-intersected genes (N = 102) and the CV-tagged genes (N = 103) were both enriched with immune-inflammatory
pathway genes (FDR q < 0.20), and the two gene sets were interconnected (permutation p = 0.039). The molecular
network representing CVs and rare-CNV association genes fit into a core/periphery structure, the immune genes and
their related modules are found at the coherence core of all connections, suggesting its dominant role in the BA
pathogenesis pathway.
Conclusions: The study highlights a patient-complexity phenomenon as a novel BA phenotypic feature, which
is underpinned by rare-CNVs that biologically converge with CVs into the immune-inflammatory pathway and
drives the BA occurrence and the likely BA association with immune diseases in clinics.
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Background
Extra-hepatic biliary atresia (or biliary atresia, BA
[OMIM 210500]) is a rare disease that manifests within
the first few months of life and is characterized by an
idiopathic, destructive, inflammatory process affecting
both intra- and extra-hepatic bile ducts. BA is diagnosed
anatomically through operative cholangiograms, in
which visualized obstruction of the extra-hepatic bile
ducts confirms the disease clinical diagnosis [1]. How-
ever, clinical manifestations of the disease, e.g. symptom
onset, treatment response, and the disease outcome [2],
vary among patients, whether BA is an end phenotype of
multiple disease process has been questioned [2]. Eluci-
dating the extent and the source of the disease pheno-
type variance thus to develop an effective disease
treatment strategy is one major task in both basic and
clinical studies of BA.
BA can be categorized according to the anatomical
features, i.e. the coexistence with systemic anomalies
(syndromic BA versus non-syndromic BA), or the ana-
tomical location of the atretic segment (type I and II ver-
sus type III BA). Yet most patients are non-syndromic
and type III BA, which comprises ~95% of BA cases in
Asians. The type III BA can be corrected by Kasai oper-
ation, but even with successful bile drainage in a major-
ity of the cases, only about 10% of the patients can have
a long-term survival with their native livers, which
reflects that the BA phenotype can be more complex be-
yond the clinical diagnosis based on the anatomy.
Etiopathogenic stratification of BA is yet to be prac-
tical. The disease etiology involves multiple plausible risk
factors, including viral infections, developmental anom-
alies, and immunity disorders, yet none of these has con-
solidated evidence with mechanistic proof for their
causal relationship with BA. In-depth exploration on the
disease endo-phenotype is hurdled by our lack of know-
ledge of the liver development, especially that at the
perinatal period when BA occurs. Meanwhile, results
from the clinical epidemiological studies can be confus-
ing due to the rarity and the complex pathogenic mech-
anism of BA.
Genetic variants are associated with BA [1]. We previ-
ously showed that common variants with footprints of
genetic-environmental interaction confer risk of BA. Also,
a handful of rare mutations has been detected in syn-
dromic BA or non-syndromic BA with severe clinical
manifestations [3–7]. Overall, BA represents a rare disease
with a complex genetic architecture. We anticipate that
the phenotypic impact of common and rare genetic
variants, especially the rare variants with major effect size,
can be explored to decipher the BA phenotypic variance
and/or heterogeneity.
Trying to bridge the genotype-phenotype gap, the chal-
lenge of the genetic analysis on BA are the uncertainty of
the BA phenotype and its complexity, the low survival rate
that makes pedigree data scarce, and also the power
of discovery issue given the rarity of the disease.
Although exploration on the developmental candidate
gene mutation in BA was fruitful, its value is limited
as individual finding that may represent only a het-
erogeneous group of patients [5–7].
For a genome-wide exploration of the impact of rare
genetic variants on BA, the study of large genomic varia-
tions, i.e. copy number variants (CNVs), is ideal to start
with, given its technical advantages, the straightforward-
ness regarding functional interpretation, and import-
antly, the fact that BA does co-occur with chromosomal
diseases, which implicate a possible role of gene dosage
variations in BA aetiology [8].
This study started with a genome-wide survey on the
association of rare CNVs. The BA clinical manifestations
reviewed with a median clinical follow-up of ~17 years
post-Kasai operation, as we think that in-depth pheno-
typing of the disease can be achieved by reviewing the
patients’ chronic disease course. After the dissection of
the CNV-genotypes–phenotype correlations (GPCs), the
rare CNVs and the GPCs were collated with common
genetic variants to examine their role in the disease gen-
etic architecture. The output would not only enhance
our understanding of the BA clinical phenotype vari-
ance/heterogeneity but also can provide a framework of
dissecting the GPCs of a rare complex disease.
Methods
Subjects
Up to March 2014, the clinical records of patients had
been stored in the computer system administered by the
government hospital authority and were retrospectively
reviewed in this study. Patients in the genome-wide
association study on BA were recruited from August 1st,
2005 to October 31st, 2007 [9]. After the pre-CNV-
calling sample quality control (QC), 89 Chinese patients
from Hong Kong remained and were reviewed for their
full clinical records, who represent non-syndromic type
III Southern Chinese BA patients with long-term sur-
vivals with/without their native livers. The patients (42
males and 47 females) were born from June 15th, 1981
to September 17th, 2007). Up to March 2014, clinical
follow-up of these patients had been conducted for a
median of 17 years 2 months (from 6.29 to 32.57 years,
interquartile range, IQR ~ 10.00 to 22.61 years). Thirty
patients had liver transplantation after Kasai operation.
After the recruitment two patients passed away between
2006 and 2013, one patient was from liver failure
while waiting for the transplantation and the other
patient from intractable seizures at 2 years after liver
transplantation.
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Two sample sets with genome-wide CNV profiles were
employed as the reference of novelty evaluation of the
CNVs discovered in BA: 1). Database of Genomic Variant
(DGV) data (http://dgv.tcag.ca/dgv/app/home; last accessed
in July 2014) that includes 11,943 individuals from different
ethnic groups genotyped on various chips with different
coverage; 2) 1,381 Chinese Han normal individuals geno-
typed on Illumina Human 610-Quad BeadChips [10].
Patients recruited in the previous GWAS study but do
not have accessible full clinical follow-up records are not
included in the analysis. The control samples in the
GWAS were not included in this study because of the
difference on copy number genotyping platform [9].
The gene-based genome-wide association analysis
employed the 289,118 single nucleotide polymorphisms
(SNPs) genotyped on 181 type III isolated BA patients
and 481 matched controls, which had undergone SNP-
based QCs as reported [9]. Principal component analysis
was performed as described and was incorporated in the
association test [9].
CNV calling and quality control
Intensity measurements from all autosomal SNP probes
and non-polymorphic copy number (CN) probes were
used to identify deletions and duplications based on 3
software, Birdseye [11] (of Birdsuite v1.5.5 package),
PennCNV [12] and iPattern [13]. Only concordant calls
by all the three programs with the segments ≧100 kb
and covered by at least 5 probes were considered for
the downstream analysis. As the MHC region (chr6:
25, 000, 000–35, 000, 000) and the centromeric and telo-
meric regions are likely to harbor spurious CNV calls we
removed any CNV segment with >50% overlap with these
regions. Details of the calling process are described in
Additional file 1: Supplementary methods and Figure S1.
We termed a CNV as a BA-CNV in the manuscript if it
was not found in the reference dataset (11,943 DGV sam-
ples, and the 1,381 Chinese samples), which was defined
technically as a CNV that did not overlap with >50% of
the CNV length with any reference CNVs at the same
direction as for dosage effect. The BA-CNVs then were
validated by quantitative real-time Polymerase Chain
Reaction (PCR) (ABI Prism 7900 Sequence Detection
System; Applied Biosystems) using TaqMan® Copy
Number Assay (Additional file 1: Supplementary materials).
For function interpretation, boundaries of the called
CNV regions were extended by 30 kb both downstream
and upstream, and the CNVs were considered to affect
the dosage of a gene if they intersected with RefSeq
exonic regions. Genotype/gene and phenotype associa-
tions were explored in the DisGeNet portal (http://
www.disgenet.org/) and DECIPHER (https://decipher.
sanger.ac.uk/). For gene-phenotype associations, only those
with genomic association proof were considered, and all
disease associations of interesting gene/genotypes
were then verified by a literature search in NCBI
(http://www.ncbi.nlm.nih.gov/).
Gene-based genome-wide association study
Gene-based association analysis congregates the effect of
multiple SNPs within each genetic locus to elucidate the
disease-associated genes, for this purpose KGG (Know-
ledge-based Genome-wide Genetic association) software
as a gene-based association test program was applied to
perform the test [14]. In addition, liver and lymphoblas-
toid expression quantitative trait loci (eQTL) in the GTEX
database were also employed (http://www.gtexportal.org/;
last assessed in December 2014). We arbitrarily selected
genes with eQTL SNP BA-association p < 5×10−3 as BA
association genes (Additional file 2: Tables S2–3 and
Additional file 1: Figure S2).
Interconnectivity of BA-CNVs and SNPs, and the genetic
network
Four hundred and forty canonical pathways from KEGG,
BIOCARTA, PID and ST were retrieved from GSEA
(http://software.broadinstitute.org/gsea; last assessed in
November 2015), and only those with 20 to 200 compo-
nent genes were included. The intersection of the genes
affected by the novel CNVs with the pathway gene sets
was tested using 1 side Fisher’s exact test for statistical
significance. For SNPs, enrichment in the functional
gene sets was tested by i-GSEA program [15]. Associ-
ation significance under the multiple-testing framework
was evaluated through Benjamini and Horchberg false
discovery rate (FDR) q value [16], q < 0.05 is statistically
significant, while q < 0.20 would be considered
noteworthy.
The interconnectivity test between the two gene sets
tagged by CNVs and SNPs as well the following gene net-
work construction was based on the protein-protein inter-
action (PPI) meta database InWeb (http://www.cbs.dtu.dk/
suppl/dgf/heart_developmental_networks/) [17, 18], which
combines the interaction knowledge from multiple PPI
databases and only confident interactions were kept for
analysis. Among the 350,006 PPI in the database, we se-
lected 129,341 PPIs with confidence score ≥0.01 (3,623
self-loops, i.e. proteins that connect with themselves, were
removed). Connectivity among encoded proteins is de-
fined as the number of interactions that connect the can-
didates, while non-coding genes were excluded. Statistical
significance of the connectivity was evaluated by a random
gene sampling of 10,000 times, the connection/interaction
with an empirical p < 0.05 means that less than 5% of the
sampled gene sets of the same size establish more
connectivity than the candidate genes do, thus suggest
significant interconnectivity of the candidate genes.
Finally, in building the network we allowed at the most 3
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interactors in the graph to link two candidate genes
(~proteins) even if they do not have direct interactions, a
random cut off would be applied if more than 3 interac-
tors exist between the pairs of candidates.
Results
Phenotype: the Non-syndromic BA is not isolated
The gene/genotype and phenotype correlation analysis
include 89 patients with a full clinical record and 86 out
of the 89 patients with confident CN callings (Additional
file 1: Supplementary methods). Retrieval of patients’
long-term medical record (median ~ 17.2 years) showed
that up to 41.57% of the non-syndromic type III BA pa-
tients have been affected by other chronic conditions
(Table 1). Hematological disorders affected 11.24% of the
patients, in which Glucose-6-Phosphate Dehydrogenase
(G6PD) deficiency occurred 14.29% of the BA male pa-
tients, whereas ~4.8% of males in the Hong Kong have the
condition [19]. Chronic autoimmune-atopic diseases
followed to affect 22.4% of the patients after the Kasai pro-
cedure, including autoimmunity occurred in 5.6% of the
patients before liver transplantation, comparing to the dis-
ease prevalence of 3.1% in the local population, while
long-lasting or recurrent atopic conditions remarkably
have attacked more than one-sixth of the patients.
Except for the structural developmental anomaly has
been described in BA and affects 5.62% of our patients
(non-syndromic BA because they carry only one such
anomaly), the relationship of the comorbidities with BA
can be a coincidence from a random chance or can sug-
gest disease-disease associations driven by the sharing of
disease etiopathogenesis. The remarkably high incidence
of comorbidities in the young BA patients, indeed, support
a possible association between BA and the comorbidities
while bringing up the patient complexity issue of the non-
syndromic BA patients that requires a follow-up study.
Genotype: BA-CNVs and genotype-phenotype correlations
Twenty-six of the 86 patients carry at least one CNV
that each spans more than 100 kb and has been found in
patients only referring to the CNV profile in the general
population (Table 2). The CNV burdens between the
patients with comorbidities and those without are not
significantly different (Chi-Square p = 0.71). Yet interest-
ingly, concurring with the high incidence of immunity
disorders in the patients, the BA-CNV regions are
Table 1 Frequency of extra-hepatic conditions in BA patients
Category Extra-hepatic diseases N. patients Prevalence (%) Overall prevalence (%)
Allergic diseases Asthma 7 7.87 16.85
Eczema 9 10.11
Autoimmune diseases Psoriasis 2 2.25 5.62
Juvenile arthritis 1 1.12
Hashimoto thyroiditis 1 1.12
Type 1 diabetes mellitus 1 1.12
Hematological diseases G6PD 6 6.74 11.24
Alpha thalassemia trait 2 2.25
Thrombocytopenia 1 1.12
Pancytopenia 1 1.12
Neural& Psychiatric diseases ADHDa 2 2.25 7.87
Epilepsy 3 3.37
Depression 1 1.12
Mental retardation 1 1.12
Structural malformations Intestinal malrotation 1 1.12 5.62
Pulmonary atresia with VSDa 1 1.12
Temporal AVMa 1 1.12
Vesicoureteric reflux grade IV 1 1.12
Jejunal atresia 1 1.12
Metabolic diseases Hyperlipidemia 1 1.12
Congenital hypothyroidism 1 1.12
Others Sleep apnea 3 3.37 4.49
Deviated nasal septum and hypertrophy of nasal turbinate 1 1.12
aG6PD glucose-6-phosphate dehydrogenase, ADHD attention deficit hyperactivity disorder, VSD ventricular septal defect, AVM arteriovenous malformation
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enriched with immunity-related genes (Table 4; FDR
q < 0.10). Also, the fact that the novel variants carried by
different BA patients tend to be immunity related sup-
ports the association of the BA-CNVs with BA. Moreover,
as we analyzed the CNV profile of each patient and their
clinical record, we found 3 BA-CNVs encompassing genes
that are associated with the extra-hepatic conditions that
the 3 patients have (Table 3).
In addition, we discovered one de novo microdeletion
intersecting JAG1 in a BA patient (BA123; Additional file
2: Table S1), who was clinically diagnosed as type III BA
by intra-operative cholangiogram study. The patient
underwent liver transplantation due to liver failure be-
fore 1 year old but has no ductopenia was noted at the
time of diagnosis. We consider the JAG1 deletion as a
known genotype to BA as it has been described in the
DECIPHER database (https://decipher.sanger.ac.uk/), al-
though JAG1 is best known for its role in NOTCH sig-
naling and liver development and its association with
Alagille syndrome [20].
All the CNVs were validated by TaqMan probes. Ex-
cept for the JAG1 deletion, all were inherited from un-
affected parents.
Despite the small scale of the CNV and GPC discov-
ery, our finding suggests that indeed these rare BA-
CNVs can connect with the clinical manifestation of the
disease. However, it is intriguing to speculate whether
the patient who carries the JAG1 deletion and those who
carry immune gene duplication/deletions represent two
distinct phenotypes of BA, as it seems that the function
of those two genotypes diverges from each other. To ad-
dress the issue, we collated the rare CNVs with the BA
candidate genes generated from common variants test in
order to understand the role of BA-CNVs in the context
of the BA genetic architecture.
The BA candidate genes from genome-wide common
variants association test
Through the gene-based genome-wide association test
using SNPs, we obtained 103 candidate genes with
genome-wide significance (Additional file 1: Figure S2).
The comparison between the 103 genes tagged by SNP
associations with the genes encompassed by BA-CNVs
(N = 102) revealed one overlapped gene S100A13
(Additional file 2: Table S1 and S2), which has decreased
expression in the BA population (lymphoblastoid), and
is deleted in one BA patient. The encoded protein
S100A13 belong to the S100 protein family, which par-
ticipate in the regulation of protein phosphorylation, Ca2
+homeostasis, the dynamics of cytoskeleton constituents,
enzyme activities, and the inflammatory response [21].
S100A13 itself is required for stress-induced IL-1A and
FGF1 exportation and it is involved in inflammation and
angiogenesis [22].
SNP-based pathway enrichment was tested by synthe-
sizing the SNP associations into each functional gene
set, which only yielded the IL1R-related inflammatory
pathway with p = 1.3×10−3, FDR q = 0.16 of suggestive
disease association (Table 4). Yet, the fact the BA-CNV-
affected genes and the SNP-tagged genes that both are
most enriched with immunity-related genes indicates
possible connections between the two gene sets.
Biological convergence of the rare and the common
genetic variants
We then tested the interconnectivity between the BA-CNV
encompassed genes (N = 102) and the SNP-tagged genes
(N = 103) based on protein-protein interactions (PPIs). Ex-
cessive interactions between the encoded proteins of the
two gene sets are observed (Permutation = 10,000, empir-
ical p = 0.041; Fig. 1a), so are the overall interactions among
all the genes as they were pooled (empirical p = 0.037).
In the network built from the CNV and the SNP tagged
genes, we first looked for the nodes that interact with each
other more frequently that with others, i.e. modules, we
then interrogated the functionality of each module based
on the ranked component genes. We found that the im-
munity-related genes cluster at the largest module
(Gene = 13, including NCNV = 5, NSNP = 8) [23], and
is located at the center of the network together with
Table 2 Stats of BA-CNVs
Deletions Duplications
No. CNVs 6 21
No. Affected Genes 26 76
Average Length 187 kb 459 kb
Median Length 292 kb 458 kb
Table 3 CNV genotypes that correlate with BA patients’ clinical phenotype
Patients Comorbidity CNV location Gene Human phenotype
BA99 Diabetes Mellitus type 1 16:81947921-82095870 (dup) PLCG2 PLCG2-associated antibody deficiency and immune
dysregulation; diabetes mellitus type 1 [33]
BA44 Hashimoto thyroiditis 18:7080664-7584939 (dup) PTPRM Autoimmune disease [34, 35]
BA68 Eczema 18:55546006-56018494 (dup) NEDD4L asthma; metabolism; hypertension disease [36, 37]
BA123 nil 20:10533666-10694525 (del) JAG1 Alagille syndrome, BA [7]
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3 other closely connected modules showing cohesive-
ness in function annotation structure (Fig. 1b-c;
Additional file 1: supplementary materials with nu-
merical parameters of the network).
Overall the network exhibits a cohesive core and
sparsely connected periphery structure (Fig. 1b-c). The 3
genes encompassed by BA-CNVs that show immunity re-
lated GPCs are located at the core of the network (Table 3,
Fig. 1c) [24]. Meanwhile, despite its interaction with the
core as mediated by the interactor NOTCH1 (Fig. 1b),
JAG1 is found at the periphery of the network. The same
core-periphery location is found of the modules of these
genes (Fig. 1c). Considering the network as a complex dy-
namic system that evolves with the addition/reduction of
candidate gene/genotypes or exogenous environmental
hazards, the core can be regarded as a stable facilitator in
the system of pathogenesis catering the variance among
patients, whereas JAG1 could just represent an individual
case finding.
S100A13 interacts with NDUFV3 (tagged by SNPs), a
NADH dehydrogenase that belongs to the accessory sub-
unit of the mitochondrial membrane respiratory chain
(Fig. 1b). Other S100 members in the same CNV segment
with S100A13 are more closely connected with each other
and are connected with NDUFA4, a NADH dehydrogenase
in the respiratory chain (Fig. 1c). The connection of S100
with the NADH dehydrogenase and its role in Ca2+ homeo-
stasis indicate that its involvement in BA can be related to
mitochondrial function. We speculate whether this could
be linked with the over-representation of G6PD deficiency
in BA. Yet indeed, the interconnections among the S100
members driven by a single BA-CNV invite our concerns
that the importance of the module in the BA genetic
network can be inflated and warrant further validations.
Discussion
The comorbidities of BA used to be recognized as a list
of developmental anomalies that present before or at the
BA diagnosis, which suggests that developmental defects
can be associated with BA [25–27]. Due to the disease
severity and rarity, the BA comorbidities that appear at
the late phase of the disease course can be neglected.
While humans are more likely to be affected by chronic
diseases as we age, that 41.52% of the BA patients of a
median age ~17 years are affected by additional chronic
diseases is extraordinary, which reflects the patient com-
plexity issue of BA that not only warrants follow-ups of
patients’ life quality in the clinical settings but also can
represent a novel phenotypic feature of the non-
syndromic BA.
Indeed, comorbidities can indicate a disease-disease
association, whereby statistical test on the relative risk
of the disease incidence as well as disease etiopatho-
genic interrogation represents the two complementing
approaches to dissect such connections. Intriguingly,
the disease-disease association can open a new win-
dow to interpret the diseases phenotype like BA, as
whereas the disease pathology itself is difficult to de-
lineate due to our lack of knowledge of the human
liver biology, the disease identity can be elucidated
from its connections with other diseases.
In our comorbidity list based on the 89 patients
with ‘full’ clinical record and long-term follow-ups,
about 5.6% of BA had autoimmunity disorders before
LT compared to the 3.1% disease incidence in the
local population, which coincides with a previously
report in the Caucasian population where 44% of BA
patients have first-degree relatives affected with auto-
immune disorders [26]. Altogether 22.47% of our BA
patients have been affected with chronic immune-
atopic diseases, these diseases frequently require
steroids treatment that overlaps with the post-
portoenterostomy steroid administration to BA [28].
Although relative risks detected for these comorbidi-
ties are very modest to suggest the association of BA
with these immunity disorders [29], the findings
reminded us that immunity deregulation has been
postulated to play a major role in BA pathogenesis
[30], which notably, has been supported by transcrip-
tome analysis and candidate gene-based association
tests [31].
Meanwhile, the BA-CNVs in these patients also are as-
sociated with immunity-related phenotypes. With the
shortlisted 29 BA-CNVs that each spans >100 kb and
are found in BA only, we tried out the ‘genotypes first’
approach [32], whereby we interpreted the functional
consequences of BA-CNVs according to the phenotype
they are associated with. Interestingly, we found that
BA-CNVs can correlate with the comorbidities in the
patients. Moreover, the immune-inflammatory processes
consistently proved to dominate the molecular network
underpinning the BA pathogenesis.
Table 4 Gene set enrichment analysis on genes encompassed
by CNVs and SNPs
Gene seta Pb FDR qb
Genes encompassed by BA-CNVs
Antigen_processing_ubiquitinaination_
proteasome_degradation
1.05 × 10−3 0.070
Signaling_by_the_B_cell_recepceptor_BCR 2.39 × 10−3 0.096
Class_I_MHC_mediated_antigen_
processing_presentation
1.95 × 10−3 0.096
Genes tagged by SNP associations
IL1R_pathway 1.30 × 10−3 0.16
aIL1R pathway in the listed gene sets are from BIOCARTA database, the others
enlisted are from REACTOME; bThe association stats on CNVs and SNPs were
obtained from different statistical test as described in methods
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Following the GPC discovery, we performed the
genome-wide gene-based SNP association test to eluci-
date the BA candidate genes that may provide us a
framework of the BA genetic landscape, and with its ref-
erence, the role of the GPCs and the BA-CNVs can be
interrogated. Common variants require much fewer
samples for the power of association discovery, and we
got 103 genes though the cases control association test.
While the connection between the CNV and the SNP at
the molecular level indirectly fortifies the association of
BA-CNVs with BA (permutation test p = 0.041), it also
granted us a chance to explore further about our GPC
findings.
The positive GPCs are small scaled but are interesting
that JAG1 known to the biliary embryonic development
and the other 3 genes known to immunity disorders are
Fig. 1 The molecular network of BA. a The direct interactions between the genes tagged by common and rare genetic variants are shown by solid lines
while indirect interactions by dashed lines. Interactions that are only mediated by interactors are not shown. *Number of protein-coding genes that have
interactions in the interactome database that we employed. b The protein network. Plotted by Gephi via the Force Atlas the ‘power-based’ approach
(https://gephi.org/). Each node designates a protein encoded by the BA candidate genes (labeled), or an interactor that mediates the connection of two
candidates, the edge of the network represent the PPIs. Colors represent the module classes of the nodes that are set to not overlap with each other while
the node size is set to be proportional to its centrality in the network. c The core-periphery structure of the network. Left upper panel: at the center of the
network the functional modules closely connect and seem to pile upon each other, while at the periphery the connection is sparse; right upper panel: the
network of meta-nodes that grouped all the nodes in each module. The size of the meta-node is proportional to its centrality. The major meta-nodes
belong at the core of the network and are connected with triangles between each other contrasting with the sparsely located periphery nodes; lower
panel: the color column denotes the functional modules, on its left side are the candidate genes of top centralities with BA-CNV encompassed genes
underlined, on the right side are the function annotation of each module that was inferred from the shared functionality of its representative genes
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enlisted, which indicate the possible existence of disease
heterogeneity. We then located these interesting genes
in the network of BA as a genetically complex disease,
which proved again the core position of immunity-
inflammation genes in BA coordinating the pathogenic
process, which otherwise can be a difficult challenge due
to our lack of knowledge about liver immunobiology,
especially that in the developmental stages.
Meanwhile ‘negative’ GPCs are expected. We believe
that the outlined GPCs between the BA-CNVs and the
immunity comorbidities of BA may just showcase the
link between the genotype and the disease phenotype.
Actually, only about 40% of the human genes have
phenotype coverage according to the OMIM and
ClinVar, the two most popular genetic association data-
bases. Even for genes with known disease associations,
the variance of expression and the allelic heterogeneity
is the norm. The genetic network hereby ‘smooths’ the
bias and incompleteness of our knowledge, as the func-
tionality of a gene can be inferred from its interacting
genes and location in the network.
Overall, we admit there are limitations of the study as a
cross-sectional analysis. The comparison of the comorbid-
ity prevalence in BA and that in the general population is
only roughly matched, as several parameters cannot be ad-
dressed e.g. the age group variance, gender difference, etc.
BA-CNVs represent the large CNVs that were found in
BA only against a large reference set, yet small CNVs
intersect important genes can have been neglected while
the platform variance between BA and the reference data
set could have invited false discoveries. Last but not least,
this is a rare complex disease study on a single population
and is limited to the number of patients with the complete
medical record only, we expect that replication survey in
additional populations on both the phenotype and geno-
type findings can complete the story.
Conclusions
Reconciling the findings at genotypic and phenotypic
levels, our results suggest that a molecular network of
rare and common genetic variants converge biologically
in an inflammatory pathway that underpins the BA
pathogenesis and drives the comorbidity of BA with im-
munity disorders. Moreover, from the patient complexity
phenomenon and also the likely association of BA with
immunity disease, we anticipate that a disease-disease
network can exist for BA, which can help decode the BA
phenotype from its location in the network while our
knowledge of the liver development and immunobiology
is still being updated. Yet indeed, putting this rare dis-
ease into a disease community requires a multi-centre
research network to overcome the challenges posed by
the analysis of small sample sizes.
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